Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Income from Continuing Operations (2023 - 2025)

Monte Rosa Therapeutics' Income from Continuing Operations history spans 3 years, with the latest figure at 46135000.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations fell 173.39% year-over-year to 46135000.0; the TTM value through Dec 2025 reached 38626000.0, down 65.81%, while the annual FY2025 figure was 38626000.0, 65.93% down from the prior year.
  • Income from Continuing Operations reached 46135000.0 in Q4 2025 per GLUE's latest filing, down from 27081000.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 62859000.0 in Q4 2024 to a low of 46135000.0 in Q4 2025.
  • Average Income from Continuing Operations over 3 years is 16439416.67, with a median of 31147500.0 recorded in 2024.
  • Peak YoY movement for Income from Continuing Operations: soared 289.04% in 2024, then crashed 173.39% in 2025.
  • A 3-year view of Income from Continuing Operations shows it stood at 33252000.0 in 2023, then skyrocketed by 289.04% to 62859000.0 in 2024, then tumbled by 173.39% to 46135000.0 in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Income from Continuing Operations are 46135000.0 (Q4 2025), 27081000.0 (Q3 2025), and 12295000.0 (Q2 2025).